Tripartite Motif (Trim) Protein Ailesi: Yapı ve Fonksiyonları
Referanslar
Esposito D, Koliopoulos MG, Rittinger K. Structural determinants of TRIM protein function. Biochem Soc Trans. 2017;45(1):183-191. doi: 10.1042/BST20160325.
Reymond A, Meroni G, Fantozzi A, et al., The tripartite motif family identifies cell compartments. EMBO J. 2001;20(9):2140-51. doi:10.1093/emboj/20.9.2140.
Li Y, Wu H, Wu W, et al., Structural insights into the TRIM family of ubiquitin E3 ligases. Cell Res. 2014;24(6):762-5. doi: 10.1038/cr.2014.46.
Giraldo MI, Hage A, van Tol S, et al., TRIM Proteins in Host Defense and Viral Pathogenesis. Curr Clin Microbiol Rep. 2020;7(4):101-114. doi: 10.1007/s40588-020-00150-8.
Watanabe M, Hatakeyama S. TRIM proteins and diseases. J Biochem. 2017;161(2):135-144. doi: 10.1093/jb/mvw087.
Shang F, Taylor A. Ubiquitin-proteasome pathway and cellular responses to oxidative stress. Free Radic Biol Med. 2011;51(1):5-16. doi: 10.1016/j.freeradbiomed.2011.03.031.
Zhang Y, Zhang W, Zheng L, et al., The roles and targeting options of TRIM family proteins in tumor. Front Pharmacol. 2022;13:999380. doi: 10.3389/fphar.2022.999380.
Yang W, Gu Z, Zhang H, et al., To TRIM the Immunity: From Innate to Adaptive Immunity. Front Immunol. 2020;11:02157. doi: 10.3389/fimmu.2020.02157.
Fiorentini F, Esposito D, Rittinger K. Does it take two to tango? RING domain self-association and activity in TRIM E3 ubiquitin ligases. Biochem Soc Trans. 2020;48(6):2615-2624. doi: 10.1042/BST20200383.
Valletti A, Marzano F, Pesole G, et al., Targeting Chemoresistant Tumors: Could TRIM Proteins-p53 Axis Be a Possible Answer? Int J Mol Sci. 2019;20(7):1776. doi: 10.3390/ijms20071776.
Massiah MA, Simmons BN, Short KM, et al., Solution structure of the RBCC/TRIM B-box1 domain of human MID1: B-box with a RING. J Mol Biol. 2006;358(2):532-45. doi: 10.1016/j.jmb.2006.02.009.
Jaworska AM, Wlodarczyk NA, Mackiewicz A, et al., The role of TRIM family proteins in the regulation of cancer stem cell self-renewal. Stem Cells. 2020;38(2):165-173. doi: 10.1002/stem.3109.
Hennig J, Bresell A, Sandberg M, et al., The fellowship of the RING: the RING-B-box linker region interacts with the RING in TRIM21/Ro52, contains a native autoantigenic epitope in Sjögren syndrome, and is an integral and conserved region in TRIM proteins. J Mol Biol. 2008;377(2):431-49.
Crawford LJ, Johnston CK, Irvine AE. TRIM proteins in blood cancers. J Cell Commun Signal. 2018;12(1):21-29. doi: 10.1007/s12079-017-0423-5.
Versteeg GA, Benke S, García-Sastre A, et al., InTRIMsic immunity: Positive and negative regulation of immune signaling by tripartite motif proteins. Cytokine Growth Factor Rev. 2014;25(5):563-76. doi: 10.1016/j.cytogfr.2014.08.001.
Hatakeyama S. TRIM Family Proteins: Roles in Autophagy, Immunity, and Carcinogenesis. Trends Biochem Sci. 2017;42(4):297-311. doi: 10.1016/j.tibs.2017.01.002.
Shen Z, Wei L, Yu ZB, et al., The Roles of TRIMs in Antiviral Innate Immune Signaling. Front Cell Infect Microbiol. 2021;11:628275. doi: 10.3389/fcimb.2021.628275.
Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol. 2015;16(4):343-53. doi: 10.1038/ni.3123.
Wicherska-Pawłowska K, Wróbel T, Rybka J. Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), and RIG-I-Like Receptors (RLRs) in Innate Immunity. TLRs, NLRs, and RLRs Ligands as Immunotherapeutic Agents for Hematopoietic Diseases. Int J Mol Sci. 2021;22(24):13397. doi: 10.3390/ijms222413397.
Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 2009;22(2):240-73. doi: 10.1128/CMR.00046-08.
van Gent M, Sparrer KMJ, Gack MU. TRIM Proteins and Their Roles in Antiviral Host Defenses. Annu Rev Virol. 2018;5(1):385-405. doi: 10.1146/annurev-virology-092917-043323.
Cloherty APM, Rader AG, Compeer B, et al., Human TRIM5α: Autophagy Connects Cell-Intrinsic HIV-1 Restriction and Innate Immune Sensor Functioning. Viruses. 2021;13(2):320. doi: 10.3390/v13020320.
Ciccosanti F, Corazzari M, Casetti R, et al., High Levels of TRIM5α Are Associated with Xenophagy in HIV-1-Infected Long-Term Nonprogressors. Cells. 2021;10(5):1207. doi: 10.3390/cells10051207.
Jimenez-Guardeño JM, Apolonia L, Betancor G, et al., Immunoproteasome activation enables human TRIM5α restriction of HIV-1. Nat Microbiol. 2019;4(6):933-940. doi: 10.1038/s41564-019-0402-0.
Ylinen LM, Keckesova Z, Wilson SJ, et al., Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5α alleles. J Virol. 2005;79(18): 11580- 11587.
Neagu MR, Ziegler P, Pertel T, et al. Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. J Clin Invest. 2009;119(10):3035-3047.
Simpson S. Genetic, structural, and functional exploration of the restrictive capacity of TRIM proteins against immunodeficiency viruses. 2017, University of Oxford.
Bouazzaoui A, Kreutz M, Eisert V, et al., Stimulated trans-acting factor of 50 kDa (Staf50) inhibits HIV-1 replication in human monocyte-derived macrophages. Virology. 2006;356:79–94.
Allouch A, Liverani V, Arosio D, et al., HIV-1 acetylated integrase is targeted by KAP1 (TRIM28) to inhibit viral integration. Retrovirology. 2009;6(Suppl 2):P2. doi: 10.1186/1742-4690-6-S2-P2.
Ganser-Pornillos BK, Pornillos O. Restriction of HIV-1 and other retroviruses by TRIM5. Nat Rev Microbiol. 2019. Epub 2019/07/18. 10.1038/s41579-019-0225-2 .
Ohainle M, Kim K, Komurlu Keceli S, et. al., TRIM34 restricts HIV-1 and SIV capsids in a TRIM5α-dependent manner. PLoS Pathog. 2020;16(4):e1008507. doi: 10.1371/journal.ppat.1008507.
Gao B, Duan Z, Xu W, et al., Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain. Hepatology. 2009;50(2):424-33. doi: 10.1002/hep.23011.
Tan G, Xu F, Song H, et al. Identification of TRIM14 as a type I IFN-stimulated gene controlling hepatitis B virus replication by targeting HBx. Front Immunol. 2018;9:1872. doi: 10.3389/fimmu.2018.01872.
Tan G, Xiao Q, Song H, et al. Type I IFN augments IL-27-dependent TRIM25 expression to inhibit HBV replication. Cell Mol Immunol 2018;15:272–81. 10.1038/cmi.2016.67.
Zhang S, Guo JT, Wu JZ, et al. Identification and characterization of multiple TRIM proteins that inhibit hepatitis B virus transcription. PLoS One. 2013;8(8):e70001. doi: 10.1371/journal.pone.0070001.
Rajsbaum R, García-Sastre A, Versteeg GA. TRIMmunity: the roles of the TRIM E3-ubiquitin ligase family in innate antiviral immunity. J Mol Biol. 2014;426(6):1265-84. doi: 10.1016/j.jmb.2013.12.005.
Wang S, Chen Y, Li C, Wu Y, Guo L, Peng C, Huang Y, Cheng G, Qin FX. TRIM14 inhibits hepatitis C virus infection by SPRY domain-dependent targeted degradation of the viral NS5A protein. Sci Rep. 2016;6:32336. doi: 10.1038/srep32336.
Wang S, Chen Y, Li C, et al. TRIM14 inhibits hepatitis C virus infection by SPRY domain-dependent targeted degradation of the viral NS5A protein. Sci Rep. 2016;6:32336. doi: 10.1038/srep32336.
Pagani I, Poli G, Vicenzi E. TRIM22. A Multitasking Antiviral Factor. Cells. 2021;10(8):1864. doi: 10.3390/cells10081864.
Berthoux L. The Restrictome of Flaviviruses. Virol Sin. 2020;35(4):363-377. doi: 10.1007/s12250-020-00208-3.
Chiramel AI, Meyerson NR, McNally KL, et al. TRIM5alpha restricts flavivirus replication by targeting the viral protease for proteasomal degradation. Cell Rep. 2019;27(11):3269–83 e6. doi: 10.1016/j.celrep.2019.05.040.
Kane M, Zang TM, Rihn SJ, et al. Identification of interferon-stimulated genes with antiretroviral activity. Cell Host Microbe. 2016;20(3):392–405. doi: 10.1016/j.chom.2016.08.005.
Liu B, Li NL, Shen Y, et al. The C-terminal tail of TRIM56 dictates antiviral restriction of influenza a and B viruses by impeding viral RNA synthesis. J Virol. 2016;90(9):4369–4382. doi: 10.1128/JVI.03172-15.
Wang K, Zou C, Wang X, et al. Interferon-stimulated TRIM69 interrupts dengue virus replication by ubiquitinating viral nonstructural protein 3. PLoS Pathog. 2018;14:e1007287.
Manokaran G, Finol E, Wang C, et. al., Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness. Science. 2015;350(6257):217–221.
Laurent-Rolle M, Morrison J, Rajsbaum R, et. al., The interferon signaling antagonist function of yellow fever virus NS5 protein is activated by type I interferon. Cell Host Microbe. 2014;16(3):314–327. doi: 10.1016/j.chom.2014.07.015.
Di Pietro A, Kajaste-Rudnitski A, Oteiza A, et al. TRIM22 inhibits influenza A virus infection by targeting the viral nucleoprotein for degradation. J Virol. 2013;87(8):4523-33. doi: 10.1128/JVI.02548-12.
Chelbi-Alix MK, Quignon F, Pelicano L, et. al., Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. J Virol. 1998;72(2):1043- 1051.
Patil G, Zhao M, Song K, et al. TRIM41-mediated ubiquitination of nucleoprotein limits influenza A virus infection. J Virol. 2018;JVI. 00905-18.
Lee HR, Lee MK, Kim CW, et al., TRIM Proteins and Their Roles in the Influenza Virus Life Cycle. Microorganisms. 2020;8(9):1424. doi: 10.3390/microorganisms8091424.
Sun N, Jiang L, Ye M, et al., TRIM35 mediates protection against influenza infection by activating TRAF3 and degrading viral PB2. Protein Cell. 2020;11(12):894-914. doi: 10.1007/s13238-020-00734-6.
Wang X, Xiong J, Zhou D, et al., TRIM34 modulates influenza virus-activated programmed cell death by targeting Z-DNA-binding protein 1 for K63-linked polyubiquitination. J Biol Chem. 2022;298(3):101611. doi: 10.1016/j.jbc.2022.101611.
Gack MU, Shin YC, Joo CH, et al., TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature. 2007;446:916–920. doi: 10.1038/nature05732.
Hu Y, Li W, Gao T, et al., The Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon Production by Interfering with TRIM25-Mediated RIG-I Ubiquitination. J. Virol. 2017;91 doi: 10.1128/JVI.02143-16.
Raheem Juhi Al-Kaabi N, Khameneh SC, Montazeri M, et al., On the relationship between tripartite motif-containing 22 single-nucleotide polymorphisms and COVID-19 infection severity. Hum Genomics. 2022;16(1):33. doi: 10.1186/s40246-022-00394-z.
Wang Y, Fan Y, Huang Y, et al., TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2. Cell Signal. 2021;85:110064. doi: 10.1016/j.cellsig.2021.110064.
Taylor RT, Lubick KJ, Robertson SJ, et al., TRIM79α, an interferon-stimulated gene product, restricts tick-borne encephalitis virus replication by degrading the viral RNA polymerase. Cell Host Microbe. 2011;10(3):185-96. doi: 10.1016/j.chom.2011.08.004.
Intlekofer AM, Finley LWS. Metabolic signatures of cancer cells and stem cells. Nat Metab. 2019;1(2):177-188. doi: 10.1038/s42255-019-0032-0.
Huang N, Sun X, Li P, et al., TRIM family contribute to tumorigenesis, cancer development, and drug resistance. Exp Hematol Oncol. 2022;11(1):75. doi: 10.1186/s40164-022-00322-w.
Ma X, Ma X, Qiu Y, et al., TRIM50 suppressed hepatocarcinoma progression through directly targeting SNAIL for ubiquitous degradation. Cell Death Dis. 2018;9(6):608. doi: 10.1038/s41419-018-0644-4.
Cao J, Su B, Peng R, et al., Bioinformatics analysis of immune infiltrates and tripartite motif (TRIM) family genes in hepatocellular carcinoma. J Gastrointest Oncol. 2022;13(4):1942-1958. doi: 10.21037/jgo-22-619.
Su H, Tang Y, Nie K, et al., Identification Prognostic Value and Correlation with Tumor-Infiltrating Immune Cells of Tripartite-Motif Family Genes in Hepatocellular Carcinoma. Int J Gen Med. 2022;15:1349-1363. doi: 10.2147/IJGM.S341018.
Fan W, Du F, Liu X. TRIM66 confers tumorigenicity of hepatocellular carcinoma cells by regulating GSK-3β-dependent Wnt/β-catenin signaling. Eur J Pharmacol. 2019;850:109-117. doi: 10.1016/j.ejphar.2019.01.054.
Zhang Z, Xu C, Zhang X, et al., TRIM11 Upregulation Contributes to Proliferation, Invasion, and EMT of Hepatocellular Carcinoma Cells. Oncol Res. 2017;25(5):691-699. doi: 10.3727/096504016X14774897404770.
Guo P, Qiu Y, Ma X, et al., Tripartite motif 31 promotes resistance to anoikis of hepatocarcinoma cells through regulation of p53-AMPK axis. Exp Cell Res. 2018;368(1):59-66. doi: 10.1016/j.yexcr.2018.04.013.
Sun G, Sui X, Han D, et al., TRIM59 promotes cell proliferation, migration and invasion in human hepatocellular carcinoma cells. Pharmazie. 2017;72(11):674-679. doi: 10.1691/ph.2017.7659.
Chao J, Zhang XF, Pan QZ, et al., Decreased expression of TRIM3 is associated with poor prognosis in patients with primary hepatocellular carcinoma. Med Oncol. 2014;31(8):102. doi: 10.1007/s12032-014-0102-9.
Wang Y, He D, Yang L, et al., TRIM26 functions as a novel tumor suppressor of hepatocellular carcinoma and its downregulation contributes to worse prognosis. Biochem Biophys Res Commun. 2015;463(3):458-65. doi: 10.1016/j.bbrc.2015.05.117.
Shen H, Zhang J, Zhang Y, et al., Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway. Gene. 2019;698:50-60. doi: 10.1016/j.gene.2019.02.044.
Li H, Zhang Y, Hai J, et al., Knockdown of TRIM31 suppresses proliferation and invasion of gallbladder cancer cells by down-regulating MMP2/9 through the PI3K/Akt signaling pathway. Biomed Pharmacother. 2018;103:1272-1278.
Peng R, Zhang PF, Zhang C, et al., Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling. Cancer Med. 2018;7(3):796-808.
Sun Y, Ren D, Yang C, et al., TRIM15 promotes the invasion and metastasis of pancreatic cancer cells by mediating APOA1 ubiquitination and degradation. Biochim Biophys Acta Mol Basis Dis. 2021;1867(11):166213.
Sun J, Yan J, Qiao HY, et al., Loss of TRIM29 suppresses cancer stem cell-like characteristics of PDACs via accelerating ISG15 degradation. Oncogene. 2020;39(3):546-559. doi: 10.1038/s41388-019-0992-2.
Xie W, Zhang Y, Wang B, et al., Tripartite motif containing 24 regulates cell proliferation in colorectal cancer through YAP signaling. Cancer Med. 2020;9(17):6367-6376. doi: 10.1002/cam4.3310.
Han Y, Tan Y, Zhao Y, et al. TRIM23 overexpression is a poor prognostic factor and contributes to carcinogenesis in colorectal cancer. J Cell Mol Med. 2020;24(10):5491–500.
Wang S, Zhang Y, Huang J, et al., TRIM67 Activates p53 to Suppress Colorectal Cancer Initiation and Progression. Cancer Res. 2019;79(16):4086-4098. doi: 10.1158/0008-5472.CAN-18-3614.
Pan S, Deng Y, Fu J, et al., TRIM52 promotes colorectal cancer cell proliferation through the STAT3 signaling. Cancer Cell Int. 2019;19:57. doi: 10.1186/s12935-019-0775-4.
Ping M, Wang S, Guo Y, et al., TRIM21 improves apatinib treatment in gastric cancer through suppressing EZH1 stability. Biochem Biophys Res Commun. 2022;586:177-184. doi: 10.1016/j.bbrc.2021.07.040.
Li R, Xu P, Jin X, et al., TRIM50 Inhibits Proliferation and Metastasis of Gastric Cancer via Promoting β-Catenin Degradation. J Oncol. 2022 ;2022:5936753. doi: 10.1155/2022/5936753.
Farhadi J, Goshayeshi L, Motavalizadehkakhky A, et al., Decreased expression of TRIM3 gene predicts a poor prognosis in gastric cancer. J Gastrointest Cancer. 2022;53(1):179-186. doi: 10.1007/s12029-020-00563-0.
Lan Q, Tan X, He P, et al., TRIM11 Promotes Proliferation, Migration, Invasion and EMT of Gastric Cancer by Activating β-Catenin Signaling. Onco Targets Ther. 2021;14:1429-1440. doi: 10.2147/OTT.S289922.
Xia Y, Wei Z, Huang W, et al., Trim47 overexpression correlates with poor prognosis in gastric cancer. Neoplasma. 2021;68(2):307-316. doi: 10.4149/neo_2020_200708N706.
Zhou W, Chen H, Ruan Y, et al., High Expression of TRIM15 Is Associated with Tumor Invasion and Predicts Poor Prognosis in Patients with Gastric Cancer. J Invest Surg. 2021;34(8):853-861. doi: 10.1080/08941939.2019.1705443.
